請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5020
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳惠文(Huei-Wen Chen) | |
dc.contributor.author | Yuh-Lin Chuang | en |
dc.contributor.author | 莊諭霖 | zh_TW |
dc.date.accessioned | 2021-05-15T17:51:01Z | - |
dc.date.available | 2014-10-09 | |
dc.date.available | 2021-05-15T17:51:01Z | - |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-18 | |
dc.identifier.citation | 1. Swartz, M.E., UPLC™: An Introduction and Review. Journal of Liquid Chromatography & Related Technologies, 2005. 28(7-8): p. 1253-1263.
2. Wren, S.A.C. and P. Tchelitcheff, Use of ultra-performance liquid chromatography in pharmaceutical development. Journal of Chromatography A, 2006. 1119(1–2): p. 140-146. 3. Snyder, L.R., J.J. Kirkland, and J.W. Dolan, Introduction to modern liquid chromatography. 2011: John Wiley & Sons. 4. Weston, A. and P.R. Brown, High Performance Liquid Chromatography & Capillary Electrophoresis: Principles and Practices. 1997: Academic Press. 5. Meyer, V.R., Practical high-performance liquid chromatography. 2013: John Wiley & Sons. 6. Takats, Z., et al., Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science, 2004. 306(5695): p. 471-473. 7. Berkenkamp, S., et al., Measurements of mean initial velocities of analyte and matrix ions in infrared matrix-assisted laser desorption ionization mass spectrometry. Journal of the American Society for Mass Spectrometry, 2002. 13(3): p. 209-220. 8. Gross, J.H., Mass spectrometry: a textbook. 2004: Springer. 9. Hoffmann, E., Mass spectrometry. 1996: Wiley Online Library. 10. Fernandez-Maestre, R., C. Wu, and H.H. Hill Jr, Using a buffer gas modifier to change separation selectivity in ion mobility spectrometry. International Journal of Mass Spectrometry, 2010. 298(1–3): p. 2-9. 11. Novakova, L., L. Matysova, and P. Solich, Advantages of application of UPLC in pharmaceutical analysis. Talanta, 2006. 68(3): p. 908-918. 12. Galhena, A.S., et al., Enhanced Direct Ambient Analysis by Differential Mobility-Filtered Desorption Electrospray Ionization-Mass Spectrometry. Analytical Chemistry, 2010. 82(22): p. 9159-9163. 13. Lapthorn, C., F. Pullen, and B.Z. Chowdhry, Ion mobility spectrometry-mass spectrometry (IMS-MS) of small molecules: Separating and assigning structures to ions. Mass Spectrometry Reviews, 2013. 32(1): p. 43-71. 14. Levin, D.S., et al., Characterization of Gas-Phase Molecular Interactions on Differential Mobility Ion Behavior Utilizing an Electrospray Ionization-Differential Mobility-Mass Spectrometer System. Analytical Chemistry, 2005. 78(1): p. 96-106. 15. Blagojevic, V., et al., Differential Mobility Spectrometry of Isomeric Protonated Dipeptides: Modifier and Field Effects on Ion Mobility and Stability. Analytical Chemistry, 2011. 83(9): p. 3470-3476. 16. Schneider, B.B., et al., Chemical Effects in the Separation Process of a Differential Mobility/Mass Spectrometer System. Analytical Chemistry, 2010. 82(5): p. 1867-1880. 17. Kanu, A.B., et al., Ion mobility–mass spectrometry. Journal of Mass Spectrometry, 2008. 43(1): p. 1-22. 18. Schneider, B., T. Covey, and E. Nazarov, DMS-MS separations with different transport gas modifiers. International Journal for Ion Mobility Spectrometry, 2013. 16(3): p. 207-216. 19. Creaser, C.S., et al., Ion mobility spectrometry: a review. Part 1. Structural analysis by mobility measurement. Analyst, 2004. 129(11): p. 984-994. 20. Porta, T., E. Varesio, and G. Hopfgartner, Gas-Phase Separation of Drugs and Metabolites Using Modifier-Assisted Differential Ion Mobility Spectrometry Hyphenated to Liquid Extraction Surface Analysis and Mass Spectrometry. Analytical Chemistry, 2013. 85(24): p. 11771-11779. 21. Nutt, D.J., L.A. King, and L.D. Phillips, Drug harms in the UK: a multicriteria decision analysis. The Lancet. 376(9752): p. 1558-1565. 22. Schweizer, E. and K. Rickels, Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatrica Scandinavica, 1998. 98: p. 95-101. 23. Poyares, D., et al., Chronic benzodiazepine usage and withdrawal in insomnia patients. Journal of Psychiatric Research, 2004. 38(3): p. 327-334. 24. Koob, G.F., Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends in Pharmacological Sciences, 1992. 13(0): p. 177-184. 25. Rowlett, J.K., et al., Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. Proceedings of the National Academy of Sciences of the United States of America, 2005. 102(3): p. 915-920. 26. Chan, A.W.K., Effects of combined alcohol and benzodiazepine: A review. Drug and Alcohol Dependence, 1984. 13(4): p. 315-341. 27. Martin, L., et al., Enhanced recognition of facial expressions of disgust in opiate users receiving maintenance treatment. Addiction, 2006. 101(11): p. 1598-1605. 28. O’Brien, C.P., Benzodiazepine use, abuse, and dependence. J Clin Psychiatry, 2005. 66(Suppl 2): p. 28-33. 29. Chun-Jen Chen, I., et al., Drug abuse-related accidents leading to emergency department visits at two medical centers. Journal of the Chinese Medical Association, 2012. 75(5): p. 234-239. 30. Marin, S.J., et al., Quantitation of Benzodiazepines in Urine, Serum, Plasma, and Meconium by LC-MS-MS. Journal of Analytical Toxicology, 2008. 32(7): p. 491-498. 31. Schuckit, M.A., Drug and alcohol abuse: A clinical guide to diagnosis and treatment. 2006: Springer. 32. de Armas, H.N., et al., Polymorphism of alprazolam (XanaxR): A review of its crystalline phases and identification, crystallographic characterization, and crystal structure of a new polymorph (form III). Journal of Pharmaceutical Sciences, 2007. 96(5): p. 1114-1130. 33. Wennerholm, A., et al., Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of α- and 4-hydroxy metabolites in healthy subjects. European Journal of Clinical Pharmacology, 2005. 61(2): p. 113-118. 34. Verster, J.C. and E.R. Volkerts, Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature. CNS Drug Reviews, 2004. 10(1): p. 45-76. 35. Levine, B., Forensic toxicology. Analytical chemistry, 1993. 65(5): p. 272A-276A. 36. Blagojevic, V., G. Koyanagi, and D. Bohme, Multi-Component Ion Modifiers and Arcing Suppressants to Enhance Differential Mobility Spectrometry for Separation of Peptides and Drug Molecules. Journal of The American Society for Mass Spectrometry, 2014. 25(3): p. 490-497. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5020 | - |
dc.description.abstract | 本研究利用液相層析串聯質譜儀(Ultra-performance liquid chromatography; UPLC-MS/MS)搭配離子遷移光譜術(Differential Ion Mobility Spectrometry; DMS) 開發一快速、高選擇性以及高靈敏度的方法分析人類尿液中之濫用藥物及其代謝物。DMS最重要的功能為可以提高選擇性以及改善訊噪比(signal-to-noise ratio),以實現定量樣品中的微量分析物。在DMS中,高分離電壓 (SV) 與有機溶劑之修飾劑 (例如,異丙醇、乙腈及其混合物) 將加入DMS的漂移氣體裡。苯二氮類藥物之半衰期較快,是一種常見的醫療鎮靜安眠劑,但是,在刑事案件上常發現被用來降低被害者的知覺能力,使其喪失意志,而對被害者進行身體或財物的侵害。在苯二氮類藥物裡,alprazolam為常見的濫用藥物之一。Alprazolam的半衰期是大約12到15小時左右。使用與分析物相關的補償電壓(Compensation voltage; CoV),以選擇性DMS離子通過質量分析器,找出利用液相層析串聯質譜儀與搭配離子遷移光譜術,可檢測尿液中微量之殘留代謝產物,可以測定吃藥後6天在尿液樣品中之alprazolam和它代謝物α-hydroxyalprazolam的含量。再現性分為intra-day, inter-day (n=3) 皆少於14%,線性範圍為0.1-100 ng mL-1,線性回歸係數R2 ≧0.998。本方法延展一般鎮靜安眠藥在尿液中的檢出時間(12-48小時),至藥物使用後之6天,有利於釐清此類藥物在醫療上或犯罪上之使用角色。 | zh_TW |
dc.description.abstract | The present work describes a rapid, selective and sensitive approach coupling ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and modifier-assisted differential ion mobility (DMS) spectrometry mass spectrometry to investigate drugs of abuse and their metabolites in urine. The most important feature of DMS is the increase the selectivity and improving the signal-to-noise ratio to achieve lower limits of detection in the range of sample. In DMS the combination of a high separation voltage (SV) together with organic modifier (e.g., IPA, ACN) added in the drift gas. An analyte-dependent compensation voltage (CoV) was applied to selective ions through the DMS cell to the mass analyzer. Benzodiazepines are selected as the analytes, which are common sedative hypnotic agents. Recently they have been found to reduce the defensing ability of assault victims in crime. Using our investigated method, alprazolam and its metabolites, α-hydroxyl-alprazolam was identified in real urine samples after administration of alprazolam for 5-6 days. We here showed the development of a sensitive technique and looked for stable metabolites to detect in urine compounds of interest at trace level. The linear range of the method was 0.1 to 100 ng mL-1 for all benzodiazepines, linear plots yielded R2 ≧ 0.998. And the limits of detection (LODs) ranged from 0.1 to 1 ng mL-1 , the residual standard deviation (RSD) ranged from 2~14%. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:51:01Z (GMT). No. of bitstreams: 1 ntu-103-R01447010-1.pdf: 4098727 bytes, checksum: c5931f2fe8510a704cbf7c77a12f648e (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Table of Contents
Acknowledgments........................................................................................i 中文摘要.................................................................................................... ii English Abstract ........................................................................................ iv List of Figures ......................................................................................... viii List of Tables ............................................................................................ ix Chapter 1 Introduction ................................................................................ 1 1.1 Background and Motivation .............................................................. 1 1.1.1 Ultra-performance liquid chromatography (UPLC) .................... 1 1.1.2 Mass spectrometry (MS) ............................................................. 2 1.1.3 Differential ion mobility spectrometry (DMS) ........................... 3 1.1.4 Benzodiazepines .......................................................................... 5 1.1.5 Alprazolam .................................................................................. 7 1.2. Research purpose .............................................................................. 8 Chapter 2 Material and methods ................................................................. 9 2.1 Chemicals and Reagents .................................................................... 9 2.2 Instrument .......................................................................................... 9 2.2.1 Liquid Chromatography-Mass Spectrometry (LC-MS).............. 9 2.2.2 Differential Ion Mobility and Mass Spectrometry (DMS-MS) . 10 2.3 Method validation ............................................................................11 2.3.1 Calibration curve .......................................................................11 2.3.2 Accuracy ....................................................................................12 2.4 Preparation of real sample ...............................................................12 2.4.1 Collection urine sample .............................................................12 vii 2.4.2 Acid hydorolysis of urine samples ............................................12 2.5 Software and equation for data acquisition ..................................... 13 Chapter 3 Result and discussion ...............................................................14 3.1 Evaluation of optimized condition ..................................................14 3.1.1 Scan multiple reaction monitoring (MRM) mode parameters ..14 3.1.2 Consider of optimized modifier ................................................14 3.2 Validation ........................................................................................19 3.2.1 Linearity .....................................................................................19 3.2.2 Limit of detection (LOD) ..........................................................20 3.2.3 Accuracy ....................................................................................20 3.3 Application in real urine sample ......................................................20 Chapter 4 Conclusion ................................................................................22 Reference ..................................................................................................42 | |
dc.language.iso | en | |
dc.title | 利用液相層析串聯質譜儀搭配離子遷移光譜術分析尿液中之苯二氮類藥物 | zh_TW |
dc.title | Analysis of Benzodiazepine in Urine Using Liquid Chromatography Ion Mobility Spectrometry
Tandem Mass Spectrometry | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳珮珊(Pai-Shan Chen) | |
dc.contributor.oralexamcommittee | 薛景中(Jing-Jong Shyue),郭錦樺(Ching-Hua Kuo) | |
dc.subject.keyword | 液相層析串聯質譜儀,離子遷移光譜術,苯二氮類藥物,有機溶劑之修飾劑,Alprazolam, | zh_TW |
dc.subject.keyword | Ultra-performance liquid chromatography-mass spectrometry,Differential ion mobility spectrometry,Modifier,Benzodiazepines,Urine, | en |
dc.relation.page | 48 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 4 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。